[EN] INHIBITORS OF PI3 KINASE AND / OR MTOR<br/>[FR] INHIBITEURS DE LA PI3 KINASE ET/OU DU MTOR
申请人:AMGEN INC
公开号:WO2010126895A1
公开(公告)日:2010-11-04
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
[EN] HETEROARYL COMPOUNDS AS PIKK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE EN TANT QU'INHIBITEURS DES PIKK
申请人:AMGEN INC
公开号:WO2010132598A1
公开(公告)日:2010-11-18
The present invention provides compounds that are PIKK inhibitors, more specifically, mTOR and/or PI3Kα kinase inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PI3 kinases, more specifically, mTOR and/or PI3Kα, such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof;
methods of treating diseases or conditions, such as cancer, using the compounds; and
pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
The present invention provides compounds that are PIKK inhibitors, more specifically, mTOR and/or PI3Kα kinase inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PI3 kinases, more specifically, mTOR and/or PI3Kα, such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof;
methods of treating diseases or conditions, such as cancer, using the compounds; and
pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.